Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) FCF Margin (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed FCF Margin for 6 consecutive years, with 1575.07% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, FCF Margin rose 451850.0% year-over-year to 1575.07%, compared with a TTM value of 302.94% through Sep 2025, up 1091460.0%, and an annual FY2024 reading of 5047.19%, changed N/A over the prior year.
  • FCF Margin was 1575.07% for Q3 2025 at X4 Pharmaceuticals, down from 1517.08% in the prior quarter.
  • Across five years, FCF Margin topped out at 4173.17% in Q2 2023 and bottomed at 6093.57% in Q3 2024.
  • Average FCF Margin over 4 years is 205.34%, with a median of 814.5% recorded in 2025.
  • The sharpest move saw FCF Margin crashed -957477bps in 2024, then soared 451850bps in 2025.
  • Year by year, FCF Margin stood at 1671.94% in 2022, then skyrocketed by 150bps to 4173.17% in 2023, then tumbled by -153bps to 2202.4% in 2024, then grew by 28bps to 1575.07% in 2025.
  • Business Quant data shows FCF Margin for XFOR at 1575.07% in Q3 2025, 1517.08% in Q2 2025, and 42.93% in Q1 2025.